A Open-Label Ascending Dose Study to Evaluate the Safety and Effects of PR001A in Patients With Parkinson's Disease

Brief description of study

This is a 5 year study and the purpose is to assess the safety and tolerability of 2 dose levels of PR001A administered via l injection in patients with moderate to severe Parkinson's Disease

Eligibility of study

You may be eligible for this study if you meet the following criteria:

Conditions:
Parkinson's Disease
Age: Between 35 Years - 80 Years
Gender: All

Male or Female Age 35-80 (BMI) of 18 to 34 Diagnosis of Parkinson's Disease

Updated on 04 Apr 2024. Study ID: 843759

You have contacted , on

Your message has been sent to the study team at ,

A copy of the message has been sent to your email

What happens next?

You can expect the study team to contact you via email or phone in the next few days.
Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

By sending a message, I agree that my data will be sent to a representative for the selected site and processed in accordance with this website's Privacy Policy (see link in footer).